International

ATC Code: L02AE02. Hormones and related agents. Gonadotropin-releasing hormone analogues.

This product has been developed based on proprietary technology owned by GP Pharm.

Dosage: 22.5 mg

Dosage form: powder and solvent for extended-release injectable suspension

Format: 1 vial of 22.5 mg and 1 syringe of 2 mL

Therapeutic indications:

• Treatment of advanced hormone-sensitive prostate cancer.
• Treatment of locally advanced hormone-sensitive prostate cancer, in combination with radiotherapy.
• Treatment of localized hormone-sensitive prostate cancer in patients at intermediate or high risk, in combination with radiotherapy.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €300.99

ATC code: L02AE02. Hormones and related agents. Gonadotropin-releasing hormone analogues.

This product has been developed based on a patented technology owned by GP Pharm.

Dosage: 3.75 mg

Dosage form: powder and solvent for prolonged-release suspension for injection

Format: 1 vial and 2 mL pre-filled syringe

Therapeutic indications:

• Palliative treatment of advanced hormone-dependent prostate cancer.
• Uterine fibroids.
• Endometriosis.
• Advanced breast cancer in pre- and perimenopausal women.
• Adjuvant treatment of hormone-sensitive early-stage breast cancer in pre- and perimenopausal women.
• Ovarian protection in premenopausal women with neoplastic disease.
• Central precocious puberty (CPP).

ATC Code: H05AA02. Parathyroid hormones and analogues.

Dosage: 250 µg/ml (20 µg/80 µl)

Dosage form: pre-filled pen injectable solution

Format: 1 pre-filled pen of 2.4 ml

Therapeutic indications:

• Treatment of osteoporosis in postmenopausal women and in men with an increased risk of fracture.
• Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men with an increased risk of fracture.

ATC Code: H01CC01. Hypothalamic hormones. Antigonadotropin-releasing hormones.

Dosage: 0.25 mg / 0.5 mL

Dosage form: Solution for injection in pre-filled syringe

Format: Box with 1 pre-filled syringe. Box with 5 pre-filled syringes

Therapeutic indications:

Prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive technologies (ART).

ATC Code: H01BB03. Posterior pituitary hormones. Oxytocin and analogues.

Carbetocin in pre-filled syringe. Ready for administration.

Dosage: 100 µg

Dosage form: solution for injection in pre-filled syringe

Format: 5 pre-filled syringes of 1 ml

Therapeutic indications:

• Prevention of postpartum hemorrhage (caesarean section or vaginal delivery) due to uterine atony.

ATC code: H01CB01. Hypothalamic hormones. Somatostatin and its analogues.

Dosage: 3 mg

Dosage form: powder and solvent for solution for infusion

Format: 25 vials with lyophilised powder and 25 ampoules of solvent

Therapeutic indications:

1. Treatment of gastrointestinal bleeding due to rupture of oesophageal varices.

2. Adjuvant in the treatment of secretory pancreatic fistulas of at least 500 mL/day.

ATC code: H01CB02. Hypothalamic hormones. Somatostatin and analogues.

Dosage: 50 µg/ml, 100 µg/ml, 200 µg/ml, 500 µg/ml

Dosage form: solution for injection and infusion

Format: 5 ampoules of 1 ml for the 50, 100 and 500 µg/ml dosages. 1 vial of 5 ml for the 200 µg/ml dosage

Therapeutic indications:

• Treatment of patients with acromegaly.
• Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumours.
• Prevention of complications following pancreatic surgery.
• Control of bleeding caused by gastro-oesophageal varices in patients with cirrhosis.
• Treatment of TSH-secreting pituitary adenomas.